Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 at 50 uM after 30 mins by competitive SPR analysis relative to control
Antagonist activity at mouse GRP1-PH domain (1 to 127 residues) assessed as reduction in PI(3,4,5)P3/GRP1-PH interaction at 50 uM after 30 mins by competitive SPR analysis relative to control
Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction at 50 uM after 30 mins by competitive SPR analysis relative to control
Antagonist activity at human AKT1-PH domain (1 to 121 residues) assessed as reduction of AKT1-PH interaction with PC/PE/PS/PI(3,4,5)P3 after 30 mins by competitive SPR analysis
Antagonist activity at mouse GRP1-PH domain (1 to 127 residues) assessed as reduction in PI(3,4,5)P3/GRP1-PH interaction after 30 mins by competitive SPR analysis
Antagonist activity at human BTK-PH domain (2 to 170 residues) assessed as reduction in PI(3,4,5)P3/BTK-PH interaction after 30 mins by competitive SPR analysis
Antagonist activity at human Tapp1-PH domain (180 to 305 residues) assessed as reduction in PI(3,4)P2/Tapp1-PH interaction after 30 mins by competitive SPR analysis
Antagonist activity at GST-tagged human AKT1-PH domain (1 to 121 residues) assessed as reduction in PC/PE/PS/PI(3,4,5)P3/AKT1-PH interaction at 50 uM by liposome pull-down assay
Effect on membrane fluidity in PC/PE/PS liposome assessed as DPH probe anisotropy changes at 15 uM incubated for 30 mins by fluorescence anisotropic analysis
Effect on membrane fluidity in PC/PE/PS liposome assessed as NBD-PE probe anisotropy changes at 15 uM incubated for 30 mins by fluorescence anisotropic analysis